Literature DB >> 10477778

The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.

V De Stefano1, I Martinelli, P M Mannucci, K Paciaroni, P Chiusolo, I Casorelli, E Rossi, G Leone.   

Abstract

BACKGROUND: Point mutations in the factor V gene (factor V Leiden) and the prothrombin gene (the substitution of A for G at position 20210) are the most common causes of inherited thrombophilia. Whether or not factor V Leiden increases the risk of recurrent deep venous thrombosis is controversial, and there is no information on the risk of recurrence among carriers of both mutations.
METHODS: We studied a retrospective cohort of 624 patients who were referred for a first episode of deep venous thrombosis. After excluding 212 patients with other inherited or acquired causes of thrombophilia, we compared 112 patients who were heterozygous carriers of factor V Leiden with 17 patients who were heterozygous for both factor V Leiden and the prothrombin mutation and 283 patients who had neither mutation. The relative risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards model.
RESULTS: Patients who were heterozygous for factor V Leiden alone had a risk of recurrent deep venous thrombosis that was similar to that among patients who had neither mutation (relative risk, 1.1; 95 percent confidence interval, 0.7 to 1.6; P=0.76). In contrast, patients who were heterozygous for both factor V Leiden and the prothrombin mutation had a higher risk of recurrent thrombosis than did carriers of factor V Leiden alone (relative risk, 2.6; 95 percent confidence interval, 1.3 to 5.1; P=0.002). When the analysis was restricted to patients with spontaneous recurrences (i.e., ones that occurred in the absence of transient risk factors for venous thrombosis), the risk among carriers of both mutations, as compared with carriers of factor V Leiden alone, remained high (relative risk, 3.7; 95 percent confidence interval, 1.7 to 7.7; P<0.001), particularly if the first event had also been spontaneous (relative risk, 5.4; 95 percent confidence interval, 2.0 to 14.1; P<0.001). In contrast, the risk of recurrence in the presence of transient risk factors was similar among carriers of both mutations and carriers of factor V Leiden alone.
CONCLUSIONS: The risk of recurrent deep venous thrombosis is similar among carriers of factor V Leiden and patients without this mutation. Carriers of both factor V Leiden and the G20210A prothrombin mutation have an increased risk of recurrent deep venous thrombosis after a first episode and are candidates for lifelong anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477778     DOI: 10.1056/NEJM199909093411104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  55 in total

1.  Risk factors for thromboembolism: pathophysiology and detection.

Authors:  S Solymoss
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

2.  Heterozygosity for factor V Leiden and G20210A prothrombin genotypes in a patient with mesenteric vein thrombosis.

Authors:  Amar Al-Juburi; Margie A Scott; Hemendra R Shah; Jean-Pierre Raufman
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 3.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

4.  Diagnosis and treatment of deep vein thrombosis.

Authors:  D Ofri
Journal:  West J Med       Date:  2000-09

Review 5.  [Current controversies in the diagnosis and management of cerebral venous and dural sinus thrombosis].

Authors:  S Schwarz; M Daffertshofer; T Schwarz; D Georgiadis; R W Baumgartner; M Hennerici; C Groden
Journal:  Nervenarzt       Date:  2003-08       Impact factor: 1.214

6.  Acute superior mesenteric venous thrombosis results in high rates of readmission and morbidity.

Authors:  Elizabeth Andraska; Lindsey Haga; Katherine Reitz; Xiaoyi Li; Rafael Ramos; Efthymios Avgerinos; Michael Singh; Mohammad Eslami; Michel Makaroun; Rabih Chaer
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2020-03-03

7.  Mesenteric vein thrombosis in a patient heterozygous for factor V Leiden and G20210A prothrombin genotypes.

Authors:  Paras Karmacharya; Madan Raj Aryal; Anthony Donato
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.

Authors:  Marc Ruivard; Christine Berger; Abdellaziz Achaibi; Claude Campagne; Pierre Philippe
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

9.  Continuous Qualitative Electroencephalography as a Noninvasive Neuromonitor.

Authors:  Zachary D Threlkeld; Mohan Kottapally; Aimee Aysenne; Nerissa Ko
Journal:  Neurohospitalist       Date:  2016-04-05

10.  The SNPs (-1654C/T, -1641A/G and -1476A/T) of protein C promoter are associated with susceptibility to pulmonary thromboembolism in a Chinese population.

Authors:  Changtai Zhu; Ting Jiang; Yafang Miao; Sugang Gong; Kebin Cheng; Jian Guo; Xiaoyue Tan; Jun Yue; Jinming Liu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.